

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS/ACCEPTED PUBLISHED (2017)			
S0777	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without Intent for immediate autologous stem-cell transplant (SWOG S0777): a randomized, open label, phase 3 trial. BGM Durie, A Hoering, MH Abidi, SV Rajkumar, MD, J Epstein, S Kahanic, M Thakuri, F Reu, C Reynolds, R Sexton, R Orlowski, B Barlogie, A Dispenzieri. <u>The Lancet</u> 2017 Feb 4;389(10068):519-527. Epub 2016 Dec 23. PMID28017406; PMC pending. https://www.ncbi.nlm.nih.gov/pubmed/28017406	4/1/08	2/1/12
MYELOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2017)			
S1221	SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173). AP Algazi, J Moon, B Chmielowski, RS Lo, K Kendra, C Lao, K Lewis, R Gonzalez, K Kim, J Godwin, B Curti, M Othus, A Ribas. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session. <u>J Clin Oncol</u> 35 (suppl; abstr 2578), 2017. http://abstracts.asco.org/199/AbstView_199_184767.html		

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS PUBLISHED (2016)			
S0120	Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). X Papanikolaou, A Rosenthal, M Dhodapkar, J Epstein, R Khan, F van Rhee, Y Jethava, S Waheed, M Zangari, A Hoering, J Crowley, D Alapat, F Davies, G Morgan, B Barlogie. <u>Blood Cancer Journal</u> , 2016 Mar 25;6:e410. doi: 10.1038/bcj.2016.19. PMID27015287 http://www.ncbi.nlm.nih.gov/pubmed/27015287	6/1/02	4/1/11
MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2016)			
S9003_S9805	Autotransplants should be offered early for Waldentrom macroglobulinemia (WM). B Barlogie, K Chansky, A Hoering, J J Crowley, M Dhodapkar. International Workshop for Waldenstrom's Macroglobulinemia (IWWM-9) (October 5-8, 2016, Amsterdam, Netherlands), LBA, oral (invited talk), Session 15. http://wmworkshop.org/images/Amsterdam-2016/Abstracts/Session-15/Barlogie-15.pdf	11/1/92 9/1/98	9/1/98 5/1/00
Multiple*	Disease and outcome disparities in multiple myeloma (MM): exploring the role of race/ethnicity and obesity in Cooperative Group Clinical Trials. S Ailawadhi, S Jacobus, R Sexton, AK Stewart, A Dispenzieri, MA Hussein, JA Zonder, J Crowley, A Hoering, B Barlogie, RZ Orlowski, SV Rajkumar. American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral; Blood 128:1192, 2016. [*ECOG Studies & SWOG (S9321, S0204, S0232) https://ash.confex.com/ash/2016/webprogram/Paper95415.html		

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS PUBLISHED (2015)			
S0120	Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy. MV Dhodapkar, R Sexton, R Das, L Zhang, R Sundaram, S Soni, JJ Crowley, RZ Orlowski, B Barlogie. <u>Blood</u> 2015 Oct 14 [Epub ahead of print] PMID26468228; PMC Journal – In Process http://www.ncbi.nlm.nih.gov/pubmed/26468228	6/1/02	4/1/11
S0120	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). R Khan, M Dhodapkar, A Rosenthal, C Heuck, X Papanikolaou, P Qu, F van Rhee, M Zangari, Y Jethava, J Epstein, S Yaccoby, J Crowley, N Petty, C Bailey, G Morgan, B Barlogie. <u>Haematologica</u> , Sep;100(9):1214-21. PMID26022710; PMC Journal – In Process. http://www.ncbi.nlm.nih.gov/pubmed/26022710	6/1/02	4/1/11
S1211	Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzmab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. SZ Usmani, R Sexton, S Ailawadhi, JJ. Shah, J Valent, M Rosenzweig, B Lipe, JA Zonder, S Fredette, B Durie, A Hoering, B Bartlett, RZ Orlowski. <u>Blood Cancer Journal</u> , Aug 7;5:e334, 2015. PMID26252787; PMC4558587 http://www.ncbi.nlm.nih.gov/pubmed/26252787	10/12/12	n/a
MYELOMA MANUSCRIPTS SUBMITTED (2015)			
S0120	Flow cytometry defined cytoplasmic immunoglobulin index is a major prognostic factor for progression of asymptomatic monoclonal gammopathies to multiple myeloma (subset analysis of SWOG S0120). X Papanikolaou, A Rosenthal, M Dhodapkar, J Epstein, R Khan, F van Rhee, Y Jethava, S Waheed, M Zangari, A Hoering, J Crowley, D Alapat, F Davies, G Morgan, B Barlogie. <u>Leukemia</u> , pending revision and resubmission.	6/1/02	4/1/11

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS ACCEPTED/PUBLISHED (2014)			
S0120	Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). M Dhodapkar, R Sexton, S Waheed, S Usmani, X Papanikolaou, B Nair, N Petty, JD Shaughnessy, A Hoering, J Crowley, R Orlowski, B Barlogie. <u>Blood</u> 23(1):78-85, 2014. PMID:24144643; PMC3879908 http://www.ncbi.nlm.nih.gov/pubmed/24144643	6/1/02	4/1/11
S0434	A phase II trial of Bay 43-9006 (Sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. G Srkalovic, M Hussein, A Hoering, J Zonder, L Popplewell, H Trivedi, S Mazzoni, R Sexton, R Orlowski, B Barlogie. <u>Cancer Medicine</u> , 2014 Jun 10. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24913924	3/15/06	8/15/02
None	IMWG consensus on risk stratification in multiple myeloma. W-J Chng, A Dispenzieri, C-S Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J San Miguel, P Sonneveld, S Usmani, BGM Durie, H Avet-Loiseau on behalf of the International Myeloma Working Group. <u>Leukemia</u> 28(2):269-277, 2014; 2013 Aug 26 [Epub ahead of print] PMID23974982; [reviews not within the scope of the Public Access Policy] http://www.ncbi.nlm.nih.gov/pubmed/23974982	n/a	n/a
None	International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, G Morgan, O Landgren, R Hajek, H Einsele, KC Anderson, MA Dimopoulos, PG Richardson, M Cavo, A Spencer, A K Stewart, K Shimizu, S Lonial, P Sonneveld, BGM Durie, P Moreau, RZ Orlowski. <u>Journal of Clinical Oncology</u> 32(6):587-600, 2014. PMID24419113; PMC3918540 http://www.ncbi.nlm.nih.gov/pubmed/24419113	n/a	n/a
None	New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, KC Anderson, MA Dimopoulos, H Avet-Loiseau, U-H Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, CS Chim, JJ Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, WJ Chng, P Moreau, P Sonneveld, H Ludwig, BGM Durie, JFS Miguel on behalf of the International Myeloma Working Group (IMWG). <u>Leukemia</u> 28(3):525-542, 2014. PMID24253022; (review not within scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/24253022	n/a	n/a

MYELOMA ABSTRACTS PUBLISHED/PRESENTED/ACCEPTED (2014)

S1211	SWOG 1211: Initial report on phase I trial of RVD-Elouzumab for newly diagnosed high risk multiple myeloma (HRMM). SZ Usmani, R Sexton, S Ailawadhi, J Shah, N Callander, T Zimmerman, J Valent, M Rosenzweig, B Lipe, J Zonder, S Fredette, P Richardson, SV Rajkumar, B Durie, A Hoering, RZ Orlowski. American Society for Hematology (December 6-9, 2014, San Francisco, CA), accepted, poster.	10/12/12	n/a
S1211	SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high risk multiple myeloma (HRMM).SZ Usmani, A Hoering, R Sexton, S Ailwahdi, JJ Shah, S Fredette, B Durie, JA Zonder, M Dhodapkar, SV Rajkumar, T Zimmerman, PG Richardson, RZ Orlowski. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr TPS8624), 2014. http://abstracts.asco.org/144/AbstView_144_126521.html	10/12/12	n/a

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS PUBLISHED (2013)			
S0115	Modified high-dose melphalan and autologous stem cell transplantation in the treatment of AL amyloidosis and/or high-risk myeloma: analysis of SWOG trial S0115. V Santhorawala, A Hoering, D Seldin, K Finn, S Fennessey, B Mattar, H Safah, L Holmberg, R Dean, RZ Orlowski, B Barlogie. <u>Bone Marrow Transplantation</u> 48(12):1537-1542, 2013. PMID23852321; PMC3855173 http://www.ncbi.nlm.nih.gov/pubmed/23852321	1/1/04	11/1/10
None	Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. C Fernandez de Larrea, RA Kyle, BGM Durie, H Ludwig, S Usmani, DH Vesole, R Hajek, JF San Miguel, O Sezer, P Sonneveld, SK Kumar, A Mahindra, R Comenzo, A Palumbo, A Mazumber, KC Anderson, PG Richardson, AZ Badros, J Caers, M Cavo, X LeLau, MA Dimopoulos, CS Chim, R Schotgs, A Noeul, D Fantl, U Mellqvist, O Landgren, A Chanan-Khan, P Moreau, R Ronseca, G Merlini, JJ Lahuerta, J Blade, RZ Orlowski, JJ Shaw. <u>Leukemia</u> 27(4):780-91, 2013. PMID23288300; reviews not within scope of Public Access Policy. http://www.ncbi.nlm.nih.gov/pubmed/23288300	n/a	n/a
None	International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. E Terpos, G Morgan, M Dimopoulos, M Drake, S Lentzsch, N Raje, O Sezer, R Garcia-Sanz, K Shimizu, I Turesson, T Reiman, A Jurczyszyn, G Mertini, A Spencer, X Leleu, M Cavo, N Munshi, S Rajkumar, BGM Durie, G Roodman. <u>Journal of Clinical Oncology</u> 31(19):2347-2357, 2013. PMID:23690408; [reviews not within scope of Public Access Policy] http://www.ncbi.nlm.nih.gov/pubmed/23690408	n/a	n/a
None	Novel approaches to treatment of double-refractory multiple myeloma. HC Lee, JJ Shah, RZ Orlowski. American Society of Clinical Oncology Education Book p. 302-306, 2013. PMID23714530; PMC3762449. http://www.ncbi.nlm.nih.gov/pubmed/23714530	n/a	n/a
None	Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. RZ Orlowski. <u>Seminars in Oncology</u> 40(5):634-651, 2013. PMID24135408; PMC3819933 http://www.ncbi.nlm.nih.gov/pubmed/24135408	n/a	n/a

MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2013)

S0120	Clinical, genomic, and imaging predictors of malignancy: analysis of the first U.S. cooperative group prospective clinical trial in asymptomatic monoclonal gammopathies (SWOG S0120). MV Dhodapkar, R Sexton, S Waheed, SZ Usmani, XD Papanikolaou, BP Nair, N Petty, JD Shaughnessy, A Hoering, J Crowley, RZ Orlowski, B Barlogie. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), oral presentation; <u>Journal of Clinical Oncology</u> 31(suppl;abstr 8515), 2013. http://abstracts2.asco.org/AbstView_132_114799.html	6/1/02	4/1/11
None	Strategies to overcome barriers to accrual (BtA) to NCI-sponsored clinical trials: a project of the NCI-Myeloma Steering Committee Working Group (NCI-MYSC AWG). M Weiss, MA Gertz, RD Little, V Rajkumar, S Jacobus, R Abonoour, KC Anderson, B Barlogie, NS Callander, EJ Gorak, J Matous, GM Mills, RC Kane, MS Katz, LA Jensen, J Omel, RS Orlowski, PG Richardson, NC Munshi. <u>Journal of Clinical Oncology</u> 31(suppl; abstr 8592), 2013. http://meetinglibrary.asco.org/content/114090-132	n/a	n/a

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
MYELOMA MANUSCRIPTS PUBLISHED (2012)			
Multiple	IMWG consensus on maintenance therapy in multiple myeloma. H Ludwig, BG Durie, P McCarthy, A Palumbo, J San Miguel, B Barlogie, G Morgan, P Sonneveld, A Spencer, KC Andersen, T Facon, KA Stewart, H Einsele, MV Mateos, P Wijermans, A Waage, M Beksac, PG Richardson, C Hulin, R Niesvisky, H Lokhorst, O Landgren, P Bergsagel, R Orłowski, A Hinke, M Cavo, M Attal. <u>Blood</u> 119(13):3003-3015, 2012. PMID: 22271445; PMC3321864. http://www.ncbi.nlm.nih.gov/pubmed/22271445	n/a	n/a
None	Cure models as a useful statistical tool for analyzing survival. M Othus, B Barlogie, ML LeBlanc, JJ Crowley. <u>Clinical Cancer Research</u> 18(14):3731-3736, 2012. PMID22675175; PMC3744099 http://www.ncbi.nlm.nih.gov/pubmed/22675175	n/a	n/a
MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2012)			
E3A06	Phase II trial of initial safety and toxicity prior to the phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (E3A06): a trial coordinated by the Eastern Cooperative Oncology Group. S Lonial, S Jacobus, M Weiss, R Fonseca, MV Dhodapkar, SV Rajkumar. <u>Blood</u> (ASH Annual Meeting Abstracts) 120: 4079, 2012. http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/4079?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=E3A06+&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT	2/1/2011	n/a

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	-------------------------------	---

MYELOMA MANUSCRIPTS PUBLISHED/ACCEPTED (2011)

S9321	Prognostic factor analyses of myeloma survival with Intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. B Barlogie, V Bolejack, M Schell, J Crowley. <i>Annals of Hematology</i> 90(4):423-428, 2011. PMID21153898; PMC3053415 http://www.ncbi.nlm.nih.gov/pubmed/21153898	1/15/94	10/1/00
-------	--	---------	---------

MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2011)

S0115	Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): analysis of SWOG trial S0115. V Santhorawala, A Hoering, DC Seldin, KT Finn, SA Fennessey, B Mattar, HF Safah, LA Holmberg, RM Dean, RZ Orlowski, B Barlogie. American Society of Hematology, accepted, poster presentation.	1/1/04	11/1/10
-------	--	--------	---------

MYELOMA ABSTRACTS SUBMITTED (2011)

S0120	SWOG S0120 observational trial for MGUS and asymptomatic multiple myeloma (AMM): imaging predictors of progression for patients treated at UAMS. C Heuck, R Sexton, M Dhodapkar, Q Zhang, S Usmani, B Nair, F van Rhee, A Hoering, J Crowley, JD Shaughnessy, RZ Orlowski, B Barlogie. American Society of Hematology, submitted 8/11.	6/1/02	4/1/11
-------	--	--------	--------

*Presented

**SWOG
PUBLICATIONS LIST
MYELOMA COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MYELOMA MANUSCRIPTS PUBLISHED/PRESENTED (2010)			
S0232	Lenalidomide plus high-dose dexamethasone compared with dexamethasone alone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). J Zonder, J Crowley, M Hussein, V Bolejack, D Moore, B Whittenberger, M Abidi, B Durie, B Barlogie. <u>Blood</u> , 116(26):5838-41, 2010. PMID:20876454;PMC3031379 http://www.ncbi.nlm.nih.gov/pubmed/20876454	11/1/04	5/11/07
S9321	Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. B Barlogie, M Attal, J Crowley, F van Rhee, J Szymonifka, P Moreau, BG Durie, JL Harousseau. <u>Journal of Clinical Oncology</u> 28(7):1209-1214, 2010. PMC2834471; PMID20085933. http://www.ncbi.nlm.nih.gov/pubmed/20085933	1/15/94	10/1/00
Multiple (pooled)	Survival and years of life lost in different age cohorts of patients with multiple myeloma. H Ludwig, V Bolejack, J Crowley, J Blade, JS Miguel, RA Kyle, SV Rajkumar, K Shimizu, I turesson, J Westin, P Sonneveld, M Cavo, M Boccadoro, A Pallumbo, P Tosi, JL Harousseau, M Attal, B Barlogie, AK Stewart, B Durie. <u>Journal of Clinical Oncology</u> , 28(9):1599-1605, 2010. PMID20177027. http://www.ncbi.nlm.nih.gov/pubmed?term=ludwig%20h%20survival%20and%20years%20lost http://www.ncbi.nlm.nih.gov/pubmed/20159819	n/a	n/a
MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2010)			
S0115	Modified high-dose melphalan and autologous stem cell transplantation (mHDM/SCT) in the treatment of AL amyloidosis (AL) and/or high-risk myeloma (hM): analysis of a Southwest Oncology Group trial. V Sanchirawala, V Boldjack, J Crowley, A Hoering, KT Finn, S Gennessy, DC Seldin, B Barlogie. American Society of Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); <u>Journal of Clinical Oncology</u> 28:7s, 2010 (suppl; abstr 8022); poster presentation. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=42969	2/1/04	n/a

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
MYELOMA COMMITTEE
2009**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MYELOMA MANUSCRIPTS PUBLISHED/PRESENTED (2009)			
S0204	Phase II study of thalidomide plus dexamethasone induction (followed by tandem melphalan-based autotransplantation thalidomide-prednisone maintenance for untreated multiple myeloma: A Southwest Oncology Group Trial (S0204). MA Hussein, V Bolejack, JA Zonder, BGM Drurie, AJ Jakubowiak, JJ Crowley, B Barlogie. Submitted to and rejected by <u>Blood</u> 8/08; <u>Journal of Clinical Oncology</u> 27(21):3510-3517, 2009. PMC2717757; PMID: 19546405	6/15/02	5/15/05
S9003	Long term survival in Waldenstrom macroglobulinemia - 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003). MV Dhodapkar, A Hoering, MA Gertz, SE Rivkin, J Szymonifka, JJ Crowley, B Barlogie. <u>Blood</u> , 113(4):793-796, 2009 PMC2630265; PMID: 18931340	11/1/92	9/1/98
S9003	International prognostic scoring system for Waldenstrom macroglobulinemia. P Morel, A Duhamel, P Gobbi, M Dimopoulos, M Dhodapkar, J McCoy, J Crowley, E Ocio, R Garcia-Sanz, S Treon, V Leblond, R Kyle, B Barlogie, G Merlini. <u>Blood</u> 113(18):4163-4170, 2009. PMID: 19196866	11/1/92	9/1/98
S9321	Genetic polymorphisms of EPHX1, Gsk3B, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma in myeloma. B Durie, B Van Ness, C Ramos, O Stephens, M Haznadar, A Hoering, J Haessler, M Katz G Mundy, R Kyle, G Morgan, J Crowley, B Barlogie, J Shaughnessy. <u>Leukemia</u> 23(10):1913-1919, 2009. PMID: 196547367	1/15/94	10/1/00
MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2009)			
*S0120	Role of T-cell immunity to embryonal stem (ES) cell Antigen SOX2 in the progression of myeloma. MV Dhodapkar, V Bolejack, J Shaughnessy, P Matthews, R Pickering, P Qu, A Hoering, J Crowley, B Barlogie. <u>Journal of Clinical Oncology</u> 27:15s, abst. #8522, 2009.	6/1/02	OPEN
S0434	A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434). G Srkalovic, M Hussein, V Bolejack, A Hoering, J Zonder, B Barlogie.). <u>Journal of Clinical Oncology</u> 27:15s, abst. #e19517, 2009.	3/15/06	open

NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*S9321	Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials. B Barlogie, M Attal, J Crowley, J Harousseau. <u>Journal of Clinical Oncology</u> 27:15s, abst. #8519, 2009.	1/15/94	10/1/00
S9321	Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): examining whether different variables govern different time segments of survival. J Crowley, V Bolejack, K Robert, K Anderson, B Barlogie. <u>Journal of Clinical Oncology</u> 27:15s, abst. # 8599, 2009.	1/15/94	10/1/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
MYELOMA COMMITTEE
2008**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MYELOMA MANUSCRIPTS PUBLISHED/PRESENTED (2008)				
Multiple (2627)	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J san Miguel, B Barlogie, J Harousseau, JA Zonder, M Cavo, M Zangari, M Attal, A Belch, S Knop, D Joshua, O Sezer, H Ludwig, D Vesole, J Blade, R Kyle, J Westin, D Weber, S Brinthen, R Niesvizky, A Waage, vonLilienfelf-toal M, S Lonial, GJ Morgan, RZ Orlowski, K Shimizu, KC Anderson, M Boccadoro, BG Durie, P Sonneveld, MA Hussein; International Myeloma Working Group. <i>Leukemia</i> 22(2)414-423, 2008. PMID: 18094721	Myeloma	n/a	n/a
MYELOMA ABSTRACTS PUBLISHED/PRESENTED (2008)				
*S0232 (2525)	A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of new-diagnosed multiple myeloma (NDMM): impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. JA Zonder, JJ Crowley, V Bolejack, MA Hussein, DF Moore, BF Whittenberger, MH Abidi, BG Durie, B Barlogie. <i>Journal of Clinical Oncology</i> 26(15S):459s, #8521, 2008. http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_vie&confID=55&abstractID=36278	Myeloma	11/1/04	5/11/07
S9321 (2662)	Analytical approaches for the BOAC SNP panel Association with progression free survival in myeloma. BG Van Ness, C Ramos, V Kumar, M Steinbach, BGM Durie, J Crowley, B Barlogie, A Hoering, J Haessler, DC Johnson, GJ Morgan. <i>Blood</i> 112:abst. #2715 . http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/2715?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=van+ness&searchid=1&FIRSTINDEX=0&volume=112&issue=11&resourcetype=HWCIT	Myeloma	1/15/94	10/1/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

S0120 (2406)	Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. F Zhan, B Barlogie, V Arzoumanian, Y Huang, DR Williams, K Hollmig, M Pineda-Roman, G Tricot, V van Rhee, M Zangari, M Dhodapkar, JD Shaughnessy, Jr. <u>Blood</u> 109(4):1692-1700, 2007.	Myeloma	6/1/02	
S0120 (2407)	Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. R Spisek, A Kukreja, LC Chen, P Matthews, A Mazumder, D Vesole, S Jagannath, HA Zebroski, AJG Simpson, G Ritter, B Durie, J Crowley, JD Shaughnessy Jr, MJ Scanlan, AO Gure, B Barlogie, MV Dhodapkar. <u>Journal of Experimental Medicine</u> 204(4):831-840, 2007.	Myeloma	6/1/02	

ABSTRACTS PUBLISHED/PRESENTED

*S0232 (2417)	Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. JA Zonder, J Crowley, MA Hussein, V Bolejack, DF Moore Sr, BF Whittenberger, MH Abidi, BGM Durie, B Barlogie. <u>Blood</u> 110(11):#77, 2007.	Myeloma	10/15/04	5/11/07
*E1A02 (2426)	Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an Eastern Cooperative Oncology Group trial (study E1A02). R Abonour, LA Zhang, V Rajkumar, G Srkalovic, PR Greipp, R Fonseca, M Gertz. <u>Blood</u> 110(11):#3616, 2007.	Myeloma	7/15/04	4/26/07

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9321 (2256)	Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup trial S9321. B Barlogie, RA Kyle, KC Anderson, PR Greipp, HM Lazarus, DD Hurd, J McCoy, DF Moore Jr, SR Dakhil, KS Lanier, RA Chapman, JN Cromer, SE Salmon, B Durie, JC Crowley. <u>Journal of Clinical Oncology</u> 24(6):929-936, 2006.	Myeloma	1/15/94	10/1/00
S0232 (2465)	Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. JA Zonder, B Barlogie, BGM Durie, J McCoy, J Crowley, MA Hussein. <u>Blood</u> (Letter to the Editor) 108:403, 2006. PMID: 16790586	Myeloma	10/15/04	5/11/07
ABSTRACTS PUBLISHED/PRESENTED				
S0204 (2455)	S0204: melphalan (MEL)-based tandem autotransplants (TAT) for multiple myeloma (MM) with thalidomide/ dexamethasone (TD) induction and thalidomide/ prednisone (TP) maintenance: a phase II trial of the Southwest Oncology Group. MA Hussein, AJ Jakubowiak, V Bolejack, J Zonder, J Crowley, B Barlogie. <u>Blood</u> 108:#3088, 2006.	Myeloma	6/15/02	10/15/05

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
Multiple Studies (2285)	International staging system for multiple myeloma. PR Greipp, J San Miguel, BGM Durie, JJ Crowley, B Barlogie, J Blade, M Boccadoro, JA Child, H Avet-Loiseau, RA Kyle, JJ Lahuerta, H Ludwig, G Morgan, R Powles, K Shimizu, C Shustik, P Sonneveld, P Tosi, I Turesson, J Westin. <u>Journal of Clinical Oncology</u> 23(15):3412-3420, 2005.	Myelo		
ABSTRACTS PUBLISHED/PRESENTED				
*9321 (2305)	Incidence, outcomes, and SNP genotypes show different ethnic association in patients with myeloma, assessed in SWOG and ECOG clinical trials S9321 and E9486: from the Bank on a Cure. B Van Ness, J Crowley, C Ramos, S Grindle, E Rasmussen, E Blood, A Hoering, B Barlogie, P Greipp, B Durie. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #506, 2005.	Myelo	1/15/94	10/1/00
9321 (2308)	SNP genotypes as prognostic factors associated with staging in myeloma: the first combined SNP association analysis of SWOG, ECOG, and MRC clinical trials from the Bank on a Cure. B Van Ness, J Crowley, E Blood, E Rasmussen, C Ramos, S Grindle, G Morgan, D Johnson, A Hoerign, P Greipp, B Barlogie, B Durie. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #3489, 2005.	Myelo	1/15/94	10/1/00
9321 (2306)	SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in Intergroup trial S9321 for Myeloma: from the Bank on a Cure. BG Van Ness, JC Crowley, C Ramos, S Grindle, E Rasmussen, A Hoering, P Greipp, B Barlogie, B Durie. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #3488, 2005.	Myelo	1/15/94	10/1/00
S0120 (2309)	Differential antigenic targets of anti-tumor immune response and selective immunity to stem cell associated Group B SOX proteins in preneoplastic versus malignant gammopathy. R Spisek, LC Chen, M Scanlan, A Simpson, G Ritter, E Rasmussen J McCoy, A Murray, J Krasovsky, B Durie, J Crowley, A Mazumder, S Jagannath, B Barlogie, A Gure, M Dhodapkar. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #5116, 2005.	Myelo	6/1/02	OPEN
S0120 (2223)	Gene expression profiling of bulk CD138+ plasma cells in preneoplastic gammopathy/asymptomatic myeloma Identifies distinct subsets of patients. MV Dhodapkar, F Zhan, E Rasmussen, B Burington, B Durie, J Crowley, B Barlogie, J Shaughnessy. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #1218, 2005.	Myelo TM	6/1/02	OPEN

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0204 (2307)	SWOG 0204; phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenance for multiple myeloma (MM). MA Hussein, J McCoy, A Jakubowiak, BG Durie, JJ Crowley, B Barlogie. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #1169, 2005.	Myelo	6/15/02	10/15/05
*S0232 (2281)	High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. JA Zonder, BGM Durie, J McCoy, J Crowley, JB Zeldis, L Ghannam, B Barlogie. <u>Blood</u> (ASH Annual Meeting Abstracts) 106(11): #3455, 2005.	Myelo	10/15/04	Open

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

S9628 (2140)	Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup trial Southwest Oncology Group (SWOG) S9628. MV Dhodapkar, MA Hussein, E Rasmussen, A Solomon, RA Larson, JJ Crowley, B Barlogie. <u>Blood</u> 104(12):3520-3526, 2004.	Myeloma	11/1/96	3/15/03
Multiple Studies (2032)	Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in Southwest Oncology Group chemotherapy trials. BGM Durie, J Jacobson, B Barlogie, J Crowley. <u>Journal of Clinical Oncology</u> 22(10):1857-1863, 2004.	Myeloma		

ABSTRACTS PUBLISHED/PRESENTED

*9321 (2143)	Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using Melphalan 140 mg/m ² + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of Intergroup trial S9321 in the context of IFM 90 and MRC VII trials. J Crowley, R Fonseca, P Greipp, J McCoy, B Barlogie. <u>Blood</u> 104(11): #539, 2004.	Myeloma	1/15/94	10/1/00
9321 (2303)	Extreme regression: a statistical technique for finding good or poor prognostic groups, illustrated using myeloma patient data from Intergroup trial S9321. JJ Crowley, J McCoy, M LeBlanc, B Barlogie. <u>Blood</u> 104(11):#5202, 2004.	Myeloma	1/15/94	10/1/00
*9321 (2142)	Genetic polymorphisms associated with clinical outcome in the Intergroup trial S9321, comparing high dose therapy with standard dose therapy for myeloma, on behalf of ECOG, SWOG, CALGB, and the Bank on a Cure. R Santana-Davila, J Crowley, B Durie, B Barlogie, P Greipp, B Van Ness. <u>Blood</u> 104(11): #1495, 2004.	Myeloma	1/15/94	10/1/00

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9003 (2018)	Prognostic factors and response to fludarabine therapy in Waldenstrom's Macroglobulinemia: an update of a US Intergroup trial (SWOG S9003). MV Dhodapkar, JL Jacobson, MA Gertz, JJ Crowley, B Barlogie. <u>Seminars in Oncology</u> 30(2):220-225, 2003.	Myeloma	11/1/92	11/15/97
Multiple Studies (2114)	A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. JL Jacobson, MA Hussein, B Barlogie, BGM Durie, JJ Crowley. <u>British Journal of Haematology</u> 122:441-450, 2003.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
9321 (2023)	Comparable survival in multiple myeloma (MM) with high dose therapy (HDT) employing MEL 140 mg/m ² + TBI 12 Gy autotransplants versus standard dose therapy with VBMCP and no benefit from interferon (IFN) maintenance: results of Intergroup trial S9321. B Barlogie, R Kyle, K Anderson, P Greipp, H Lazarus, J Jacobson, E Rasmussen, J Cromer, J Crowley. <u>Blood</u> 102(11):#135, 2003.	Myelo	1/15/94	10/1/00
*S9628 (2034)	High dose dexamethasone (Dex) with maintenance Dex/alpha interferon leads to improved survival in patients with primary systemic amyloidosis: results of US Intergroup Trial Southwest Oncology Group (SWOG) S9628. M Dhodapkar, J Jacobson, M Hussein, RA Larson, J Crowley, A Solomon, B Barlogie. <u>Proc of the American Society of Clinical Oncology</u> 22:566 (#2278), 2003.	Myeloma	11/1/96	3/15/03

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9210 (1711)	Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. JR Berenson, JJ Crowley, TM Grogan, J Zangmeister, AD Briggs, GM Mills, B Barlogie, SE Salmon. <u>Blood</u> 99(9):3163-3168, 2002.	Myeloma	3/15/93	10/15/97
S9803 (1708)	The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study. JK Weick, JJ Crowley, MA Hussein, DF Moore, B Barlogie. <u>Investigational New Drugs</u> 20:117-121, 2002.	Myeloma	8/15/98	12/15/99
Multiple Studies (1948)	Partitioning and peeling for constructing prognostic groups. M LeBlanc, J Jacobson, J Crowley. <u>Statistical Methods in Medical Research</u> 11:247-274, 2002.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
9321 (1979)	A simple classification to identify poor-risk untreated myeloma. PR Greipp, S Kumar, EA Blood, M Rue, J Jacobson, TM Therneau, DR Larson, KC Anderson, MM Oken, RA Kyle. <u>Blood</u> 100(11):598a (#2351), 2002.	Myeloma	1/15/94	10/1/00
Multiple Studies (1968)	Time to first progression is the best predictor of survival duration in SWOG standard dose chemotherapy studies. BGM Durie, J Jacobson, B Barlogie, J Crowley. <u>Blood</u> 100(11):210a (#790), 2002.	Myeloma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9003 (1704)	Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States Intergroup trial (Southwest Oncology Group S9003). MV Dhodapkar, JL Jacobson, MA Gertz, SE Rivkin, GD Roodman, JM Tuscano, M Shurafa, RA Kyle, JJ Crowley, B Barlogie. <u>Blood</u> 98(1):41-48, 2001.	Myeloma	11/1/92	11/15/97
Multiple Studies (1852)	Standard-dose therapy for multiple myeloma: the Southwest Oncology Group Experience. J Crowley, J Jacobson, R Alexanian. <u>Seminars in Hematology</u> 38(3):203-208, 2001.	Myeloma		
Multiple Studies (1944)	Tree-based methods for prognostic stratification. M LeBlanc. In: <u>Handbook of Statistics in Clinical Oncology</u> J Crowley, ed. Marcel-Dekker, New York, 457-472, 2001.	Myeloma		
Statistical Paper (1903)	Understanding neural networks using regression trees: an application to multiple myeloma survival data. D Faraggi, M LeBlanc, J Crowley. <u>Statistics in Medicine</u> 20:2965-2976, 2001.	Myeloma		

ABSTRACTS PUBLISHED/PRESENTED

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

ABSTRACTS PUBLISHED/PRESENTED

9321 (1682)	A protocol for triple color interphase FISH on archived bone marrow biopsies from myeloma prepared with precipitating fixatives. E Tian, K Bumm, Y Xiao, H Xu, A Li, E Williamson, B Barlogie, J Sawyer, J Shaughnessy. <u>Blood</u> 96(11):155a (#665), 2000.	Myeloma	1/15/94	8/1/97
9321 (1683)	Beta 2 microglobulin (b2M) and plasma cell labeling index (PCLI) constitute a strong prognostic index in the SWOG Intergroup transplant trial S9321: Observations on gender and age. PR Greipp, JL Jacobson, JJ Crowley, KJ Henderson, KC Anderson, RA Kyle, B Barlogie. <u>Blood</u> 96(11):152a (#653), 2000.	Myeloma	1/15/94	8/1/97

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8229 (1936)	Adaptive regression splines in the cox model. M LeBlanc, J Crowley. <u>Biometrics</u> 55:204-213, 1999.	Myeloma	10/15/82	11/15/88
8993 (1492)	High dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial. DH Vesole, JJ Crowley, R Catchatourian, PJ Stiff, DB Johnson, J Cromer, SE Salmon, B Barlogie. <u>Journal of Clinical Oncology</u> 17(7):2173-2179, 1999.	Myeloma	4/15/91	5/1/96
9321 (1895)	The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma. LM Rimsza, K Campbell, WS Dalton, S Salmon, G Willcox, TM Grogan. <u>Leukemia and Lymphoma</u> 34(3-4): 315-324, 1999.	Myeloma	1/15/94	10/1/00
ABSTRACTS PUBLISHED/PRESENTED				
*8624 (1619)	Long term follow-up on SWOG 8624, addressing the role of glucocorticoid dose intensity for remission induction, interferon for maintenance in responders, and dexamethasone + interferon for primary treatment failures. S Salmon, T Grogan, B Barlogie, J Crowley. <u>Blood</u> 94(10) Suppl 1:315a (#1410), part 1 of 2, 1999.	Myeloma	2/1/87	1/15/92
*9003 (1563)	Serum beta 2 microglobulin and IgM identify distinct prognostic subsets in patients with Waldenstrom's macroglobulinemia (WM). MV Dhodapkar, J Jacobson, M Gertz, SE Rivkin, GR Weiss, DR Gandara, RA Chapman, J Crowley, S Salmon, R Kyle, B Barlogie. <u>Blood</u> 94(10) Suppl 1:705a (#3115), part 1 of 2, 1999.	Myeloma	11/1/92	11/15/97
*9321 (1620)	Planned melphalan-total body irradiation (MEL-TBI) – based allogeneic transplantation for multiple myeloma (MM) up to age 55: an Intergroup experience (CALGB, ECOG and SWOG) under the auspices of the Southwest Oncology Group (SWOG 9321). R Desikan, S Salmon, K Anderson, R Kyle, J Crowley, B Barlogie. <u>Blood</u> 94(10) Suppl 1:346a (#1546), part 1 of 2, 1999.	Myeloma	1/15/94	Open
*Multiple Studies (1618)	High dose therapy and the age factor in multiple myeloma: evidence vs. politics. B Barlogie, A Badros, D Avers, S Salmon, J Jacobson, M LeBlanc, J Crowley. <u>Blood</u> 94(10) Suppl 1:715a (#3157), part 1 of 2, 1999.	Myeloma		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED				
9028 (1301)	Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study. SE Salmon, JJ Crowley, SP Balcerzak, RW Roach, SA Taylor, SE Rivkin, W Samlowski. <u>Journal of Clinical Oncology</u> 16(3):890-896, 1998.	Myeloma	10/1/90	5/15/94
9237 (1294)	Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study. EH Kraut, JJ Crowley, JL Wade, LR Laufman, M Alsina, SA Taylor, SE Salmon. <u>Journal of Clinical Oncology</u> 16(2):589-592, 1998.	Myeloma	3/1/93	2/15/95
Multiple Studies (1586)	Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. S Salmon, C Tangen, Myeloma Trialists' Collaborative Group. <u>Journal of Clinical Oncology</u> 16(12):3832-3842, 1998.	Myeloma		
Multiple Studies (1932)	Tree-structured statistical methods. H Zhang, J Crowley, HC Sox Jr, RA Olshen. In: <u>Encyclopedia of Biostatistics</u> P Armitage, C Theodore, eds. John Wiley & Sons, 6.Spi-Z:4561-4573, 1998.	Myeloma		
ABSTRACTS PUBLISHED				
*9210 (1473)	Alternate day oral prednisone maintenance therapy improves progression-free and overall survival in multiple myeloma patients. J Berenson, J Crowley, B Barlogie, S Salmon. <u>Blood</u> 92(10) (Suppl 1):318a (#1305), 1998.	Myeloma	3/15/93	10/15/97

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED				
8229/8624 (1460)	Some exploratory tools for survival analysis. J Crowley M LeBlanc, J Jacobson, SE Salmon. <u>In: Lecture Notes In Statistics</u> . Proceedings of the first Seattle Symposium in Biostatistics: pp. 199-229, 1997.	Myeloma		
Multiple Studies (1458)	Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. B Barlogie, S Jagannath, DH Vesole, S Naucke, B Cheson, S Mattox, D Bracy, S Salmon, J Jacobson, J Crowley, G Tricot. <u>Blood</u> 89(3):789-793, 1997.	Myeloma		
Multiple Studies (1459)	Feasibility and cost effectiveness of outpatient autotransplants in multiple myeloma. S. Jagannath, DH Vesole, M Zhang, KR Desikan, N Copeland, M Jagannath, D Bracy, R Jones, J Crowley, G Tricot, B Barlogie. <u>Bone Marrow Transplantation</u> 20:445-450, 1997.	Myeloma		
ABSTRACTS PUBLISHED				
*9003 (1337)	Phase II intergroup trial of fludarabine (FAMP) in Waldenstrom's macroglobulinemia (WM): Results of Southwest Oncology Group trial (SWOG 9003) in 220 patients. M Dhodapkar, J Jacobson, M Gertz, J Crowley, M Shurafa, S Salmon, R Kyle, B Barlogie. <u>Blood</u> 90(10) Suppl 1:577a (#2571), 1997.	Myeloma	11/1/92	Open
*8993 (1352)	High dose melphalan with autotransplant for refractory multiple myeloma (MM): Results of a Southwest Oncology Group (SWOG) phase II trial (S8993). DH Vesole, J Naile-Cromer, D Johnson, J Crowley, S Salmon, B Barlogie. <u>Blood</u> 90 (10) Suppl 1:112a (#488), 1997.	Myeloma	4/15/91	5/1/96
*9028 (1241)	Alpha interferon plus alternate day prednisone (IFN/P) improves remission maintenance duration in multiple myeloma (MM) compared to IFN alone. SE Salmon, JJ Crowley. <u>American Society of Clinical Oncology</u> 16:13a (#46), 1997.	Myeloma	10/1/90	5/15/94

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED				
8229 (908)	Evaluation of race as a prognostic factor in multiple myeloma: An ancillary of Southwest Oncology Group study 8229. MR Modiano, P Villar-Werstler, J Crowley, SE Salmon. <u>Journal of Clinical Oncology</u> 14(3):974-977, 1996.	Myeloma	10/15/82	11/15/88

ABSTRACTS PUBLISHED

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED				
8229 (1136)	A review of tree-based prognostic models. M LeBlanc J Crowley. In: <u>Recent Advances in Clinical Trial Design and Analysis</u> PF Thall ed, Kluwer Academic Publishers, 113-124, 1995.	Myeloma	10/15/82	11/15/88
8229 (1175)	Exploratory methods in survival analysis. J Crowley, M LeBlanc, R Gentleman, S Salmon. <u>IMS Lecture Notes-Monograph Series</u> 27:55-77, 1995.	Myeloma	10/15/82	11/15/88
8229 (1137)	Step-function covariate effects in the proportional-hazards model. M LeBlanc, J Crowley. The <u>Canadian Journal of Statistics</u> 23(2):109-129, 1995.	Myeloma	10/15/82	11/15/88
8624 (1103)	In reply. SE Salmon, JJ Crowley. <u>Journal of Clinical Oncology</u> 13(4):1046, 1995.	Myeloma	2/1/87	10/1/90
ABSTRACTS PUBLISHED				
9237 (1162)	Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study. E Kraut, J Crowley, J Wade, L Laufman, G Weiss, S Taylor, S Salmon. <u>Blood</u> 86(10)(Suppl 1)(#726):185a, 1995.	Myeloma	3/1/93	2/15/95

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8049 (993)	Randomized trial of vitamin A versus observation as adjuvant therapy in high risk primary malignant melanoma: A Southwest Oncology Group study. FL Meyskens Jr, PY Liu, RJ Tuthill, VK Sondak, WS Fletcher, WR Jewell, W Samlowski, SP Balcerzak, DJ Rector, RD Noyes, JJ Costanzi. <u>Journal of Clinical Oncology</u> 12(10):2060-2065, 1994.	Melanoma	7/29/81	3/15/87
8754 (916)	Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology group. VK Sondak, KJ Kopecky, PY Liu, WS Fletcher, WH Harvey, LR Laufman. <u>Anti-Cancer Drugs</u> 5:147-150, 1994.	Melanoma	1/15/89	5/1/90
ABSTRACTS PUBLISHED/PRESENTED				
8913 (964)	Phase II evaluation of merbarone in disseminated malignant melanoma: A Southwest Oncology Group study. M Slavik, PY Liu, E Kraut, R Natale, V Sondak. <u>ASCO</u> 13:398 (#1357), 1994.	Melanoma	09/01/91	06/15/93
*8921 (999)	Comparison of patient characteristics and outcome between a single institution and cooperative group phase II trial in metastatic melanoma with identical eligibility. L Flaherty, M Hussein, PY Liu, D Smith, V Sondak. <u>ASCO</u> 13:397 (#1352), 1994.	Melanoma	2/15/90	9/1/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8624 (529)	P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy. TM Grogan, CM Spier, SE Salmon, M Matzner, JA Rybski, RS Weinstein, RJ Scheper, WS Dalton. <u>Blood</u> 81(2):490-495, 1993.	Myeloma	02/01/87	10/01/90
Multiple Studies (948)	Myeloma plasma cells express a-2,8 polysialated neural cell adhesion molecule. VA Guptill, EH Hanneman, F Troy, EE Vela, EM Hersh, TM Grogan. <u>IVth International Workshop on Multiple Myeloma</u> 136 (#P-19), 1993.	Myeloma		
Multiple Studies (949)	Human myeloma cells express a complex neurogenic phenotype. E Hanneman, E Vela, V Guptill, J Moore, L Richter, T Grogan. <u>IVth International Workshop on Multiple Myeloma</u> 136 (#P-20), 1993.	Myeloma		
Multiple Studies (1051)	Polysialylated neural cell adhesion molecule (N-CAM) as an oncodevelopmental antigen and as part of a complex neurogenic phenotype in human myeloma. T Grogan, V Guptill, E Hanneman, E Vela, L Richter, J Moore, J Hemperly, F Troy. <u>IVth International Workshop on Multiple Myeloma</u> 136:37, 1993.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
8624 (833)	Quantitative PCR analysis of MDR1 mRNA in patients with multiple myeloma. BW Futscher, LL Blake, TM Grogan, WS Dalton. <u>AACR</u> 33:467 (#2792), 1992.	Myeloma	02/15/89	10/01/90
*8624 (834)	Impact of glucocorticoids (GC) and interferon (IFN) on outcome in multiple myeloma. SE Salmon, J Crowley. <u>ASCO</u> 11:316 (#1069), 1992.	Myeloma	02/01/87	10/01/90

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8108 (485)	Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study. BGM Durie, J Crowley, CA Coltman, Jr, RA Chapman, SP Balcerzak, JD Bonnet, DA Lipschitz, RL Stephens, BD Cheson. <u>IND</u> 9:329-331, 1991.	Myeloma	06/02/82	03/16/84
8229/30 (434)	Prognostic correlation of plasma cell acid phosphatase and β -Glucuronidase in multiple myeloma: A Southwest Oncology Group study. SM Saeed, D Stock-Novack, R Pohlod, J Crowley, SE Salmon. <u>Blood</u> 78(12):3281-3287, 1991.	Myeloma	12/15/83	11/15/88
8624 (491)	Alpha interferon for remission maintenance: Preliminary report on the Southwest Oncology Group study. SE Salmon, J Beckord, RP Pugh, B Barlogie, J Crowley. <u>Seminars in Oncology</u> 18(5):33-36, 1991.	Myeloma	02/01/87	10/01/90
8726 (457)	Evaluation of amonafide in refractory and relapsing multiple myeloma: A Southwest Oncology Group study. KH Hanson, J Crowley, SE Salmon, M Keppen, TJ Braun, JD Bonnet. <u>Anti-Cancer Drugs</u> 2(3):247-250, 1991.	Myeloma	04/01/88	11/01/89

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8213 (303)	Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study. C Karanes, J Crowley, L Sawkar, BL Trantum, WJ Hicks, JD Bonnet, L Dabich, BW Dana, S Salmon. <u>IND</u> 8:101-104, 1990.	Myeloma	07/21/82	09/27/85
8229/30 (306)	Prognostic value of pretreatment serum B2 microglobulin in myeloma: A Southwest Oncology Group study. BGM Durie, D Stock-Novack, SE Salmon, P Finley, J Beckord, J Crowley, CA Coltman, Jr. <u>Blood</u> 75(4):823-830, 1990.	Myeloma	12/15/83	01/15/88
8229/30 (307)	Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: A Southwest Oncology Group study. SE Salmon, D Tesh, J Crowley, S Saeed, P Finley, MS Milder, LF Hutchins, CA Coltman, Jr, JD Bonnet, B Cheson, JA Knost, A Samhouri, J Beckord, D Stock-Novack. <u>JCO</u> 8(9):1575-1584, 1990.	Myeloma	12/15/83	01/15/88
8303 (315)	A phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. MR Grever, JJ Crowley, S Salmon, R McGee, EH Kraut, SS Buys, SE Rivkin. <u>JNCI</u> 82(22): 1778-1779, 1990.	Myeloma	04/25/83	03/22/85
8409 (323)	Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. EH Kraut, JJ Crowley, MR Grever, MD Keppen, JD Bonnet, HE Hynes, SE Salmon. <u>IND</u> 8:199-200, 1990.	Myeloma	11/01/84	01/01/89
8604 (339)	A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma: A Southwest Oncology Group study. MB Edelstein, JJ Crowley, FA Valeriote, JD Bonnet, JO Carden, RC Khanna, SE Salmon, JS Ungerleider. <u>IND</u> 8:S83-S86, 1990.	Myeloma	10/15/86	12/01/87
Multiple Studies	Optimization of immunocytochemical PGP assessment in multidrug resistant plasma cell myeloma using three antibodies. TM Grogan, WS Dalton, JA Rybski, P Meltzer, L Richter, M Gleason, A Cline, RJ Scheper S Salmon. <u>Invest Lab</u> 63:815-824, 1990.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
8229/30 (355)	Immaturity and dyspoiesis scoring: A system to discriminate benign vs. malignant plasmacytic proliferation. SM Saeed, BKS Raman, R Pohlod. <u>Modern Pathology</u> 3(1):87A (#514), 1990.	Myeloma	12/15/83	11/15/88

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8229/30	Combination chemotherapy is superior to hemibody irradiation (HXRT) for remission consolidation in multiple myeloma (MM): A Southwest Oncology Group (SWOG) study. S Salmon, D Tesh, J Crowley, S Saeed, P Finley, D Stock-Novack. <u>ASCO</u> 8:250 (#975), 1989.	Myeloma	12/15/83	11/15/88
8229/30	Acid phosphatase and beta glucuronidas as prognostic factors in patients with multiple myeloma: A Southwest Oncology Group study. S Saeed, D Stock-Novack, S Salmon, J Crowley, R Pohlod. <u>Blood</u> 74(7):240A, 1989.	Myeloma	12/15/81	11/15/88

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

8310	Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: A Southwest Oncology Group study. WJ Stuckey, J Crowley, LH Baker, NR Larrimer, KH Hanson, JD Bonnet, LA White, Jr. <u>Cancer Treat Rep</u> 71(11):1095-1096, 1987.	Myeloma	12/07/84	10/01/86
------	--	---------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7927/28	Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. BGM Durie, DO Dixon, S Carter, R Stephens, S Rivkin, J Bonnet, SE Salmon, L Dabich, JC Files, JJ Costanzi. <u>JCO</u> 4(8):1227-1237, 1986.	Myeloma	09/25/79	12/01/82
---------	--	---------	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8031	Phase II trial of mitoxantrone in multiple myeloma: A Southwest Oncology Group study. DS Alberts, SP Balcerzak, JD Bonnet, RL Stephens. <u>Cancer Treat</u> <u>Rep</u> 69(11):1321-1323, 1985.	Myeloma	11/21/80	03/30/83
ABSTRACTS PUBLISHED/PRESENTED				
*7927/28	Improved survival duration with combination chemotherapy induction for multiple myeloma. BGM Durie, DO Dixon, S Carter, R Stephens, S Rivkin, J Bonnet, L Dabich, S Salmon, JC Files, JJ Costanzi. <u>ASH</u> #741, 1985.	Myeloma	09/25/79	12/01/82

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7719	Addition of Cisplatin and Bleomycin to Vincristine-Carmustine-Doxorubicin-Prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: A Southwest Oncology Group study. JD Bonnet, R Alexanian, SE Salmon, A Haut, DO Dixon. <u>Cancer Treat Rep</u> 68: 481-485, 1984.	Myeloma		
------	--	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7704/05	Alternating combination chemotherapy and Levamisole improves survival in multiple myeloma: A Southwest Oncology Group study. SE Salmon, A Haut, JD Bonnet, M Amare, JK Weick, BGM Durie, DO Dixon. <u>J Clin Oncol</u> 1:453-461, 1983.	Myeloma		
7963	Phase II evaluation of Amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: A University of Arizona and Southwest Oncology Group study. FR Ahmann, F Meyskens Jr, SE Jones, RM Bukowski, JH Saiers, DH Ryan, J Costanzi, CB Vaughn, CA Coltman Jr. <u>Cancer Treat Rep</u> 67:697-700, 1983.	Melanoma, Myeloma, Lymphoma, Lung, Breast		
*8108/16/ 17/18/19/ 20/61/ 8214	Southwest Oncology Group studies with Bisantrene. CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller, E Surwit, DS Alberts, RA Shildt, F Panettiere, GM Mills, PB Wasserman, TM McDaniel. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Bisantrene</u> 213:1-4, 1983.	Myeloma, Lymphoma, GYN, GI, Melanoma, Leukemia, Sarcoma		

ABSTRACTS PUBLISHED/PRESENTED

*7927	Tetrameric Bence Jones Proteinemia. BL Hom, M Inamasu. <u>5th Meeting of the International Society of Hematology, Asian Pacific Division</u> (Manila, January 10-15, 1983).	Myeloma		
-------	---	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7432	Vincristine, BCNU, Doxorubicin, and Prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: A Southwest Oncology Group study. J Bonnet, R Alexanian, R Bottomley, M Amare, A Haut, D Dixon. <u>Cancer Treat Rep</u> 66:1267-1271, 1982.	Myeloma		
------	--	---------	--	--

ABSTRACTS PUBLISHED/PRESENTED

7704/05	Addition of Levamisole to chemotherapy improves survival in multiple myeloma. SE Salmon. <u>Am Soc Hematol</u> , 1982.	Myeloma		
---------	--	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7305/7313 7418	Chemoimmunotherapy for multiple myeloma. R Alexanian, S Salmon, J Gutterman, D Dixon, J Bonnet, A Haut. <u>Cancer</u> 47:1923-1929, 1981.	Myeloma		
7704/05	Chemoimmunotherapy for multiple myeloma: Effect of Levamisole during maintenance. Preliminary report of a Southwest Oncology Group study. SE Salmon, R Alexanian, DO Dixon. In: <u>Immunotherapy of Human Cancer</u> . WD Terry, SA Rosenberg, eds. New York: Elsevier-North Holland, 61-66, 1981.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

7704/05	Chemoimmunotherapy for multiple myeloma: Effect of Levamisole. SE Salmon, R Alexanian, DO Dixon. <u>Immunotherapy of Cancer: Present Status of Trials in Man</u> , p. 28, April, 1980.	Myeloma		
7963	A broad Phase II trial of AMSA with <u>in vitro</u> stem cell culture drug sensitivity correlation. F Ahmann, F Meyskens, S Jones, B Durie, D Alberts, S Salmon. <u>ASCO</u> , #C-199, 1980.	Breast, Lung, Lymphoma, Melanoma, Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

ABSTRACTS PUBLISHED/PRESENTED

7704/05	Non-Cross resistant combination chemotherapy improves survival in multiple myeloma. S Salmon, R Alexanian, D Dixon. <u>Blood</u> 54:207a (#552), 1979.	Myeloma		
---------	--	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

732/735	Unmaintained remissions in multiple myeloma. R Alexanian, E Gehan, A Haut, J Saiki, J Weick. <u>Blood</u> 51(6):1005-1012, 1978.	Myeloma		
7418/7704	Clinical staging and new therapeutic approaches in multiple myeloma. SE Salmon, BGM Durie. In: <u>Recent Results in Cancer Research</u> , Vol. 65, Mathe, G., Seligmann, M., and Tubiana, M. (eds), Springer-Verlag, Berlin/Heidelberg, pp. 12-20, 1978.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7305	Combination therapy for multiple myeloma. R Alexanian, SE Salmon, J Bonnet, E Gehan, A Haut and J Weick. <u>Cancer</u> 40:2765-2771, 1977.	Myeloma		
7305	Chemotherapy for multiple myeloma. R Alexanian, SE Salmon, J Bonnet, E Gehan, A Haut and J Weick. In: <u>Recent Advances in Cancer Treatment</u> , Raven Press, New York, pp. 19-38, 1977.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
7305	Chemotherapy for multiple myeloma. R Alexanian, S Salmon, J Bonnet, E Gehan, A Haut, J Weick. <u>Recent Advances in Cancer Treatment</u> , Tagnon HJ, Staquet MJ, eds. New York, Raven Press, Monograph Series of the European Organization for Research on Treatment of Cancer. Vol. 3, 1977.	Myeloma		
7432	Vincristine-BCNU-adriamycin-prednisone combination for treatment of melphalan- and cytoxan-resistant multiple myeloma. JD Bonnet, R Alexanian and SE Salmon. <u>ASCO</u> , #C-305, 1977.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Nitrosoureas in multiple myeloma. SE Salmon. <u>Cancer Treat Rep</u> 60(6):789-794, 1976.	Myeloma		
*7435	Phase II trial of piperazinedione (crystalline antibiotic) in lymphoma and multiple myeloma. S Jones, S Salmon and members of the Southwest Oncology Group. <u>AACR</u> , #179, 1976.	Lymphoma Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1975**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
734/36/35	Remission maintenance therapy for multiple myeloma: Southwest Oncology Group study. R Alexanian, SP Balcerzak, A Haut, J Hewlett and E Gehan. <u>Arch Intern Med</u> 135:147-152, 1975.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
*7305	Combination chemotherapy for multiple myeloma. SE Salmon and BGM Durie. <u>ASH</u> , #115, 1975.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
721/2/5/6/ 7/731/3/4/6	Bone healing in multiple myeloma with melphalan chemotherapy. LH Rodriguez, JB Finkelstein, CC Shullenberger and R Alexanian. <u>Annals of Intern Med</u> 76:551-556, 1972.	Myeloma		
721/5/7	Combination chemotherapy for multiple myeloma. R Alexanian, J Bonnet, A Haut, J Hewlett, M Lane, R Monto and HE Wilson. <u>Cancer</u> 30(2):382-389, 1972.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Normal immunoglobulins in multiple myeloma. R Alexanian, PJ Migliore. <u>J Lab Clin Med</u> 75:225-233, 1970.	Myeloma		
?	Multiple myeloma: a nine-year experience with melphalan therapy at the M.D. Anderson Hospital. R Alexanian. In: <u>Leukemia-Lymphoma, 14th Annual Clinical Conference on Cancer</u> , 1969, M.D. Anderson Hospital and Tumor Institute at Houston. Year Book Medical Publishers, Inc.:305-316, 1970.	Myeloma		
?	Multiple myeloma. R Alexanian. In: <u>Current Therapy</u> 22nd Edition, Howard F. Conn, Editor. W.B. Saunders Co., Publishers, Philadelphia, PA:256-258, 1970.	Myeloma		
ABSTRACTS PUBLISHED/PRESENTED				
?	Melphalan-prednisone-procarbazine therapy for multiple myeloma. R Alexanian, J Bonnet, E Gehan, J Hewlett, M Lane, R Monto, H Wilson. In: <u>XIII Congress of the International Society of Hematology</u> , Munich, Germany:354, 1970.	Myeloma		
?	Bone healing in multiple myeloma following melphalan chemotherapy. LH Rodriguez, JB Finkelstein, CC Shullenberger, R Alexanian. <u>Xth International Cancer Congress</u> , Houston, TX, Abstract No. 790:489, 1970.	Myeloma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1969**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens. R Alexanian, A Haut, AU Kahn, M Lane, E McKelvery, PH Migliore, WJ Stuckey Jr., HE Wilson. <u>JAMA</u> (9):1680-1685, 1969.	Myeloma		
---	---	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Phase II studies of hydroxyurea (NSC-32065) in adults: Multiple myeloma and lymphoma. P Davis. <u>Cancer</u> <u>Chemotherapy Reports</u> 40:51-52, 1964.	Myeloma Lymphoma		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1963**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. W Skinner, DE Bergsagel, W Traux. <u>Cancer Chemotherapy Reports</u> 28:13-15, 1963.	Myeloma		
---	--	---------	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1962**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. VI. Measarcylisin. C Austin, DE Bergsagel, CC Sprague. <u>Cancer Chemotherapy Reports</u> 21:107-112, 1962.	Myeloma		
?	Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcylisin, and meta-sarcylisin in the treatment of multiple myeloma. DE Bergsagel. <u>Cancer Chemotherapy Reports</u> 16:261-266, 1962.	Myeloma		
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. I. Plan of Study. DE Bergsagel, CC Sprague, SW Ross. <u>Cancer Chemotherapy Reports</u> 21:69-73, 1962.	Myeloma		
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. II. Mitomycin C (NSC-26980). DE Bergsagel, SW Ross, P David. <u>Cancer Chemotherapy Reports</u> 21:75-80, 1962.	Myeloma		
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-phenylalanine mustard (NSC-8806). DE Bergsagel, CC Sprague, C Austin, KM Griffith. <u>Cancer Chemotherapy Reports</u> 21:85-99, 1962.	Myeloma		
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. V. L-aminocyclophen tanecarboxylic acid (NSC-1026). DE Bergsagel, SW Ross, DT Baker. <u>Cancer Chemotherapy Reports</u> 21: 101-106, 1962.	Myeloma		
?	Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. III. AB-100 (NSC-37095). CL Brown, DE Bergsagel, WC Levin. <u>Cancer Chemotherapy Reports</u> 21:81-85, 1962.	Myeloma		